NVO at a glance
Novo Nordisk A/S (NVO, SEC CIK 353278) filed its latest 20-F annual report on February 4, 2026 and a 6-K report on November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Novo Nordisk A/S (NVO) shares worth $4.1 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 39 funds
- $4.1B · −1 vs prior quarter
- Latest 6-K
- Nov 16, 2026
- Foreign issuer report
AI 20-F Annual Report Analysis
Latest 20-F, fiscal year ended Dec 31, 2025
Risk Factors
- Cybersecurity exposure under EU GDPR and multiple jurisdictions; third-party vendors with sensitive data access create breach and regulatory penalty risk
- Production sites in North Carolina and Indiana face hurricane/tornado risk; Tianjin facility exposed to storm surges from rising sea levels
- Water scarcity risk: substantial withdrawal from water-stressed regions threatens diabetes and biopharmaceutical manufacturing continuity
- Scope 3 decarbonisation levers (supplier renewable electricity, e-methanol, low-carbon ammonia) have delayed effect, risking climate target failure and regulatory/reputational exposure
Management Discussion & Analysis
- Revenue details, segment breakdowns, margin figures, and cash flow data not disclosed in this 20-F excerpt: all figures referenced via Annual Report 2025 incorporation
- Obesity & Diabetes Care largest segment, >90% of total sales; growth driven by GLP-1 category expansion and rising global diabetes/obesity prevalence
- Key risk: US pricing pressure intensifying, average net prices declined in 2025; rebates rising across commercial, Medicare, Medicaid, and direct-to-patient channels
- $4.2B 340B provision to be reversed and recognized as revenue in Q1 2026 following HRSA dismissal of ADR petition on 20 January 2026
- R&D spend guided at ~15–17% of sales, expected to gradually increase; 70–80% allocated to clinical development activities
Business Overview
- Global healthcare leader in obesity/diabetes care; manufactures/markets GLP-1 receptor agonists, insulins, and rare disease products across ~170 countries
- Wegovy® revenue grew 36% to DKK 79B in FY2025; Ozempic® global sales exceeded DKK 127B, though both lost US #1 GLP-1 prescription share to competing products
- Major restructuring: new CEO (Doustdar, Aug 2025), new Board Chair (Sørensen, Nov 2025), ~9,000 employees cut in company-wide transformation initiated Sept 2025
- Acquired Akero Therapeutics for $4.7B (+$0.5B CVR) in Dec 2025, targeting MASH: expansion into obesity-adjacent metabolic disease comorbidities
- Wegovy® Pill launched Q1 2026; semaglutide compound patents (Ozempic®, Rybelsus®, Wegovy®) secured via China Supreme Court ruling Dec 2025, US expiry 2032
AI summary of the NVO 20-F filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
SignalX for NVO
Don't miss the next NVO filing
- Alerts as it files. A push when NVO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NVO, by share count.
- Ask anything. An AI agent that reads every NVO filing and answers with sources.
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NVO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 39 | $4.13B |
| Q2 2026 | 40 | $4.64B |
| Q1 2026 | 39 | $3.76B |
| Q4 2025 | 42 | $6.98B |
| Q3 2025 | 43 | $7.79B |
| Q2 2025 | 43 | $7.35B |
| Q1 2025 | 40 | $6.70B |
| Q4 2024 | 38 | $4.83B |
- Two Sigma Investments+14.90M (+94292%)
- Citadel Advisors LLC+5.65M (+413%)
- Bank of America Corp+2.35M (+21%)
- Renaissance Technologies LLC+1.64M (+54%)
- Morgan Stanley+1.35M (+12%)
- T. Rowe Price Group−8.35M (-71%)
- Goldman Sachs Group−3.49M (-38%)
- Northern Trust−833.7K (-23%)
- D.E. Shaw & Co−644.1K (-92%)
- Wells Fargo & Co−457.2K (-10%)
- Bridgewater Associates LP+22.9K
- StoneX Group Inc.+11.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 324 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 20-F, 6-K
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 6-K | Nov 16, 2026 | - | - | - |
| 6-K | Nov 9, 2026 | - | - | - |
| 6-K | Nov 5, 2026 | - | - | - |
| 6-K | Nov 4, 2026 | - | - | - |
| 6-K | Nov 3, 2026 | - | - | - |
| 6-K | Oct 26, 2026 | - | - | - |
| 6-K | Oct 19, 2026 | - | - | - |
| 6-K | Oct 13, 2026 | - | - | - |
| 6-K | Oct 6, 2026 | - | - | - |
| 6-K | Oct 5, 2026 | - | - | - |
| 6-K | Sep 28, 2026 | - | - | - |
| 6-K | Sep 21, 2026 | - | - | - |
| 6-K | Sep 17, 2026 | - | - | - |
| 6-K | Sep 15, 2026 | - | - | - |
| 6-K | Sep 9, 2026 | - | - | - |
| 6-K | Aug 31, 2026 | - | - | - |
| 6-K | Aug 24, 2026 | - | - | - |
| 6-K | Aug 18, 2026 | - | - | - |
| 6-K | Aug 10, 2026 | - | - | - |
| 6-K | Aug 10, 2026 | - | - | - |
| 6-K | Aug 4, 2026 | - | - | - |
| 6-K | Aug 4, 2026 | - | - | - |
| 6-K | Aug 4, 2026 | - | - | - |
| 6-K | Jul 31, 2026 | - | - | - |
| 6-K | Jul 27, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NVO SEC filings: frequently asked questions
Which institutions hold NVO stock?
As of September 30, 2026, the largest Novo Nordisk A/S (NVO) holders among the 13F filers tracked by SignalX were Franklin Resources ($568.3 million), Two Sigma Investments ($565.4 million), Bank of America Corp ($512.8 million), Morgan Stanley ($493.1 million), Citadel Advisors LLC ($265.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in NVO's latest 20-F?
In the 20-F filed February 4, 2026, Novo Nordisk A/S (NVO) flagged: Cybersecurity exposure under EU GDPR and multiple jurisdictions; third-party vendors with sensitive data access create breach and regulatory penalty risk. Production sites in North Carolina and Indiana face hurricane/tornado risk; Tianjin facility exposed to storm surges from rising sea levels. (AI summary of the Risk Factors section.)
What are the latest NVO SEC filings?
Novo Nordisk A/S (NVO) filed its latest 20-F annual report on February 4, 2026 and a 6-K report on November 16, 2026.
What is NVO's SEC CIK number?
Novo Nordisk A/S (NVO)'s SEC Central Index Key (CIK) is 353278. EDGAR lists every NVO filing under that number.
Ask anything about NVO
The research agent reads NVO's filings, financials, insider trades and 13F holders, then answers with sources.